Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tempus AI Has A High Probability Of Profitability In 2025
Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while maintaining its high-growth trajectory. Tempus recently gained in-network provider status with Blue Cross Blue Shield across multiple states, allowing for the firm's tests to be covered by insurance.
Tempus AI jumps almost a third on health app launch
Tempus AI Inc shares skyrocketed on Tuesday after the company announced the nationwide launch of its personal health app. Known as Olivia, the app was designed to centralize patients' health data and make it accessible and actionable using artificial intelligence, Tempus said in a statement.
Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
Tempus AI is a leading player in healthcare AI, aiming to deliver personalized treatment suggestions through its proprietary data model. Preliminary Q4 results and 2025 guidance show mixed performance, with revenue slightly below expectations but positive adjusted EBITDA anticipated for 2025, driven by the Ambry Genetics acquisition. TEM's strong fundamentals and competitive position, bolstered by the Ambry acquisition, support long-term growth, particularly in diagnostics and expanding AI applications across healthcare.
TEM Stock Declines Following Preliminary Q4 Sales Miss
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
Tempus AI: A Potential Double-Bagger After Recent Pullback
In mid-August, around two months after Tempus AI's NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below their opening price of $37 as of the Dec. 18 close.
Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnostics" leverages generative AI and a vast proprietary dataset to drive personalized treatment options, positioning it as a leader in precision medicine. Financially, Tempus shows robust revenue growth but remains unprofitable; recent acquisitions and ongoing investments aim to strengthen its market position and path to profitability.
Tempus AI: Why I'm Buying This AI Stock
Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins for Tempus AI's Data & Services division position Tempus AI for significant future profitability and cash flow. AI-driven automation and advanced machine learning algorithms enhance operational efficiency, reducing costs and accelerating data analysis for better client insights.
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth, strategic acquisitions, and unique data assets create a compelling long-term investment.
